REMARKS

The specification was amended to claim the benefit of priority to prior applications. Claims 1-45 were pending before this amendment. Claims 7-9, 11-13, 15-16, 26-33, 38, 40-41, and 43-45 have been canceled for the sole reason of reducing excess claim fees. Applicant reserves the right to pursue the canceled claims in one or more continuation applications. Minor amendments have been made to claims 1-4, 6, 10, 21, 34-37, 39 and 42. No new matter has been added. Entry of the amendments prior to consideration of the application on the merits is respectfully requested.

No other fees are believed to be due in connection with this Preliminary Amendment. However, please apply any additional charges, or credit any overpayment, to our Deposit Account No. 50-3187.

Respectfully submitted,

Elaine Sale, Ph.D.
Attorney for Applicants

Registration No. 41,286

Date: May 25, 2006

Customer No. 43852 Argos Therapeutics, Inc. 4233 Technology Drive Durham, NC 27704

Tel: (919) 287-6300 Fax: (919) 287-6336



AP20 Rec'd PCT/PTO 25 May 2006

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service, Express Mail Post Office to Addressee, in an envelope addressed to the Assistant Commissioner for Patents, Mail Stop PCT, PO Box 1450,

Alexandria, VA/22313-1450

Signature

EQ725881557US

Express Mail No.